Immunotherapy Companies Leading the Charge for Treating Cancer

NEW YORK, February 21, 2017 /PRNewswire/ --

Immuno-oncology is one of the fastest growing and promising areas of cancer research. It is the genesis behind the rapidly expanding field of precision-focused cancer drug development. Immuno-oncology therapeutics is transforming the way cancer is being treated due to its ability to harness and activate a patient's own immune system and stimulate it to attack cancer cells or by introducing immune system components into the body. While some immuno-oncology treatments have the potential to be effective as monotherapies, others may be more effective when combined with other treatments. Tapimmune, Inc. (NASDAQ: TPIV), AstraZeneca plc (NYSE: AZN), Amgen, Inc. (NASDAQ: AMGN), Merck & Co., Inc. (NYSE:MRK), Juno Therapeutics, Inc. (NASDAQ: JUNO) are all leading the charge in the race to develop groundbreaking treatments for a myriad of cancers.

Encouraging results generated by some of these companies demonstrating positive results in late-stage cancer patients have raised hopes for longer-term survival of people who have advanced disease and otherwise have run out of options. According to a research report conducted by Markets and Markets the global cancer immunotherapy market is expected to reach USD 119.39 Billion by 2021 from USD 61.9 Billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer and rising healthcare expenditure are driving the growth of this market.

TapImmune, Inc. (NASDAQ: TPIV) is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease. On February 15th, the company announced that, "its lead cancer vaccine candidate, TPIV 200, received a positive recommendation from an independent Data Safety Monitoring Board (DSMB) to continue dosing triple-negative breast cancer (TNBC) patients in an ongoing Phase 2 clinical trial."

According to the company, "the planned safety review was performed when enrollment had reached 25 percent benchmark (20/80 patients). The four-arm trial is designed to test the safety, dosing level and optimal treatment regimen of TPIV 200, the company's novel five-peptide vaccine designed to elicit a long-lasting adaptive immune response against TNBC cells, involving both "helper" and "killer" T-cells. The study tests two vaccine dose levels with and without cyclophosphamide priming of the immune system and will monitor for sustained immune response and relapse-free survival for three years. TapImmune will be enrolling the remaining patients at 12 clinical centers in the U.S. with enrollment completion targeted for the end of 2017."

TapImmune, Inc. on December 30th, 2016 in a year end update, the company announced that, "a Mayo Clinic-sponsored trial evaluating TPIV 200 as a standalone agent for patients with triple negative breast cancer is anticipated to begin in 2017. The study is expected to enroll 280 patients and is fully funded thanks to a $13.3 million grant from the U.S. Department of Defense. A trial sponsored by Memorial Sloan Kettering, in collaboration with AstraZeneca, is treating patients with ovarian cancer who are platinum resistant (meaning they've failed chemo and have few options moving forward with therapy). This exciting study is testing a combination of TPIV 200 with AstraZeneca's checkpoint inhibitor, durvalumab. The combination of these two cancer immunotherapies could have a more significant effect on tumors than either drug alone."

AstraZeneca (NYSE: AZN) announced positive results from its Phase III OlympiAD trial comparing LYNPARZA™ tablets to physician's choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations. 1 Patient treated with LYNPARZA showed a statistically-significant and clinically-meaningful improvement in progression-free survival compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin). "These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive Phase III data for a PARP inhibitor beyond ovarian cancer. This is highly encouraging for the development of our broad portfolio which aims to treat multiple cancers by targeting DNA damage response pathways," said Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, Sean Bohen.

Amgen Inc. (NASDAQ: AMGN) announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration for BLINCYTO® to include overall survival data from the Phase 3 TOWER study, supporting the conversion of BLINCYTO's accelerated approval to full approval. The sBLA also includes new data supporting the treatment of patients with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The application aims to broaden BLINCYTO's indication for the treatment of patients with relapsed or refractory B-cell precursor ALL. "Acute lymphoblastic leukemia is one of the most aggressive B-cell malignancies, and adult patients who relapse or are refractory to treatment often go through multiple lines of therapy," said Executive Vice President of Research and Development at Amgen, Sean E. Harper.

Merck & Co. Inc. (NYSE: MRK) announced the launch of ILÚM Health Solutions, which provides enterprise-wide disease management tools and services to enable improved outcomes for patients with infectious diseases, such as sepsis and pneumonia, while supporting antimicrobial stewardship initiatives. ILÚM operates independently from Merck's pharmaceutical and vaccine products businesses as part of Merck's Healthcare Services & Solutions group. "We are pleased to offer ILÚM in the United States as a way to strategically partner with health systems to fight infectious diseases and combat the threat of antimicrobial resistance," said Managing Director, Guy Eiferman. "It is an important step for our Healthcare Services and Solutions business, and complements Merck's company-wide efforts to develop and deliver innovative approaches to address some of today's most pressing health issues."

Juno Therapeutics Inc. (NASDAQ: JUNO) is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia  

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com    

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com expects to be compensated seven thousand five dollars for financial news dissemination and pr services by a third party non affiliate for tapimmune, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions, expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879

URL: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com